Renin–Angiotensin–Aldosterone System Inhibitors in Patients with COVID-19: General Considerations and Clinical Implications

Renin–Angiotensin–Aldosterone System Inhibitors in Patients with COVID-19: General Considerations and Clinical Implications

Neiberg de Alcântara Lima, Eric Martin Sieloff, Pedro Yuri Paiva Lima, Ricardo Lessa de Castro Junior, Stela Maria Vitorino Sampaio

Initially reported in China at the end of 2019, the coronavirus pandemic has now reached an international scale with more than1.5 million cases worldwide and more than 80,000 deaths by April 8th of this year. Recent studies have shown that the virus invades host cells by the angiotensin-converting enzyme 2 receptor, making it essential to viral transmission. Concerns have been raised about possible benefits and harms associated with the use of angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptors blockers in these patients. However, there is lack of evidence to recommend even temporarily discontinuing renin-angiotensin system inhibitors/blockers in patients infected with the SARS-CoV-2.KEYWORDS:

2020

coronavirus, angiotensin-converting enzyme inhibitors, renin–angiotensin system, Pandemics, COVID-19

DOI: https://doi.org/10.24207/jca.v33i1.3367

Journal of Cardiac Arrhythmias

Linceu Editorial

Diseases of the circulatory (Cardiovascular) system